<DOC>
	<DOCNO>NCT00659412</DOCNO>
	<brief_summary>Randomized , double-blind , 24-week study patient psoriatic arthritis compare alefacept + methotrexate ( MTX ) vs. placebo + MTX follow 24-week open-label extension alefacept + MTX treatment .</brief_summary>
	<brief_title>A Placebo-controlled Study With Extension Examining Safety Efficacy Alefacept Psoriatic Arthritis</brief_title>
	<detailed_description>Patients complete initial 24-week treatment course meet inclusion exclusion criterion 24 week open-label extension continue stable MTX dose also receive alefacept throughout extension .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Psoriatic arthritis MTX treatment 3 month prior enrollment continue disease Normal Tcell count Other type psoriasis History malignancy lymphoproliferative disorder Serious infection fever Antibody positive Hepatitis C , HIV TB Hepatic transaminases &gt; 2X normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Alefacept</keyword>
</DOC>